The Current Treatment Bone and Mineral Metabolism (BMM) disorders content examines the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. The emphasis of this content is on calcium-phosphorus metabolism, secondary hyperparathyroidism (SHPT), and hyperkalemia. This content provides a detailed, expanded analysis and longitudinal information on the BMM market dynamics. It provides insight into practice patterns, physician attitudes and perceptions, and current and projected use of various products such as phosphate binders, nutritional and active vitamin D, and calcimimetic agents, as well as persistency, compliance, and drivers and obstacles to the use of these classes of medications. We also include sales and messaging efforts of key market players and coverage of late-stage products for the treatment of BMM.


Related Reports

Hyperphosphatemia - Current Treatment - Detailed, Expanded Analysis (US)

Hyperphosphatemia is a common complication in the later stages of chronic kidney disease (CKD). Sequelae can include hypocalcemia, disturbances in bone mineralization homeostasis, and an increased...

View Details